Document is current
Any future updates will be listed below
-
Authors
Zhao, Wanchen
Russell, Catherine Maya
Jankovsky, Anastasia
Cannon, Tyrone D.
Pittenger, Christopher
Pushkarskaya, Helen
-
Funding
Funding for this research was provided by:
National Institute of Mental Health (R01MH095790, R21MH120801)
- License Information
-
More Information
Article History
Received: 11 August 2023
Accepted: 26 April 2024
First Online: 6 May 2024
Competing interests
: Chris Pittenger has consulted in the past 12 months for Freedom Biosciences, Transcend Therapeutics, Ceruvia Lifesciences, Biohaven Pharmaceuticals, UCB BioPharma, Nobilis Therapeutics, and F-Prime Capital Partners. He receives research funding from Freedom Biosciences, Transcend Therapeutics, and Biohaven Pharmaceuticals. He holds equity in Alco Therapeutics. He has patents pending on the use of psychedelics in the treatment of obsessive-compulsive disorder, various therapeutic psychedelics and combinations, and the identification of antibodies involved in rapid-onset autoimmune neuropsychiatric disorders, none of which are relevant to the current work. He receives royalties from Oxford University Press and UpToDate. Other authors declare no competing interests.
